Balchem Corporation

10/23/2026 | Press release | Distributed by Public on 10/23/2026 14:19

Quarterly Report for Quarter Ending September 30, 2026 (Form 10-Q)

Management's Discussion and Analysis of Financial Condition and Results of Operations
(All amounts in thousands, except share and per share data)
Forward-Looking Statements
This report contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, which reflect our expectation or belief concerning future events that involve risks and uncertainties. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "forecast," "outlook," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," or the negative thereof or variations thereon or similar expressions generally intended to identify forward-looking statements. Actions and performance could differ materially from what is contemplated by the forward-looking statements contained in this report. Factors that might cause differences from the forward-looking statements include those referred to or identified in Item 1A of the Annual Report on Form 10-K for the year ended December 31, 2025 and other factors that may be identified elsewhere in this report. Reference should be made to such factors and all forward-looking statements are qualified in their entirety by the above cautionary statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Factors that may affect our forward-looking statements include, among other things: (1) our ability to manage risks associated with our sales to customers and manufacturing operations outside the United States, including changes in tariffs, sanctions, trade restrictions and trade relations, political and economic instability and geopolitical tensions; (2) supply chain disruptions due to political unrest, terrorist acts, and national and international conflicts; (3) reliability and sufficiency of our manufacturing facilities; (4) our ability to recruit and retain a highly qualified and motivated workforce; (5) our ability to effectively manage labor relations; (6) the effects of global climate change or other unexpected events, including global health crises, that may disrupt our operations; (7) our ability to manage risks related to our information technology and operational technology systems and cybersecurity; (8) our reliance on third-party vendors for many of the critical elements of our global information and operational technology infrastructure and their failure to provide effective support for such infrastructure; (9) disruption and breaches of our information systems; (10) increased competition and our ability to anticipate evolving trends in the market; (11) global economic conditions, including inflation, recession, changes in tariffs and trade relations; (12) raw material shortages or price increases; (13) currency translation and currency transaction risks; (14) interest rate risks; (15) our ability to successfully consummate and manage acquisitions, joint ventures and divestitures; (16) our ability to effectively manage and implement restructuring initiatives or other organizational changes; (17) changes in our relationships with our vendors, changes in tax or trade policy, interruptions in our operations or supply chain, political or financial instability and geopolitical tensions; (18) adverse publicity or consumer concern regarding the safety or quality of food products containing our products; (19) the outcome of any litigation, governmental investigations or proceedings; (20) product liability claims and recalls; (21) our ability to protect our brand reputation and trademarks; (22) claims of infringement of intellectual property rights by third parties; (23) risks related to corporate social responsibility and reputational matters; (24) improper conduct by any of our employees, agents or business partners; (25) changes to, or changes in interpretations of, current laws and regulations, and loss of governmental permits and approvals; and (26) regulatory requirements for ethylene oxide users that have impacted, and may continue to impact, such users' ability to use the ethylene oxide process to sterilize medical devices, among other things.
Overview
We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, performance gases, plant nutrition and industrial markets. Our three reportable segments are strategic businesses that offer products and services to different markets: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".
Balchem is committed to solving today's challenges to shape a healthier tomorrow by operating responsibly and providing innovative solutions for the health and nutritional needs of the world. Sustainability is at the heart of our company's vision to make the world a healthier place and plays an important role in our strategies and in long-term value creation for our stakeholders. Our framework focuses on the sustainability topics most relevant to our business and stakeholders, and has been fully integrated into our governance structure and everyday operations. We are very proud of our significant progress relating to the Company's corporate social responsibilities and will continue to foster these fundamental principles broadly along our entire value chain, develop new ideas and technologies that help us work smarter, and help build a world that is a better place to live.
As of September 30, 2026, we employed approximately 1,430 full time employees worldwide. Labor market conditions remained generally stable during the quarter, supporting our ability to attract and retain skilled and experienced employees in a competitive talent market. Additionally, we continued to invest in and leverage technology solutions to enhance productivity, improve performance, and drive operational efficiencies across the organization.
Recent Developments
Geopolitical Conflicts
We continue to monitor the heightened geopolitical tensions in the Middle East, including conflicts involving Iran, which have, or may have, certain effects on our business and broader consequences, including increased energy prices, certain raw material costs, increased freight costs, and volatility in shipping patterns. All above impacts may adversely affect the global economy and may have the effect of heightening the operational risks disclosed in the "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025.
Tariffs
We continue to monitor developments with respect to tariffs and other trade policy matters closely, including impacts from the U.S. Supreme Court decision in February 2026 that invalidated certain tariffs previously imposed under the International Emergency Economic Powers Act ("IEEPA"). Following the ruling, the U.S. presidential administration imposed additional tariffs under other statutory authorities, resulting in a rapidly evolving tariff environment. The online portal and process to submit IEEPA tariff refund requests became available on April 20, 2026, and since June 2026, we have participated in the process for refunds to the extent we were the importer of record and directly paid tariffs under IEEPA. We do not expect the financial impacts of these developments to have a material effect on our future results of operations or cash flows. We will continue to monitor and evaluate new information as it becomes available.
Segment Results
We sell products for all three segments through our own sales force, independent distributors, and sales agents.
The following tables summarize consolidated net sales by segment and business segment earnings from operations for the three and nine months ended September 30, 2026 and 2025:
Business Segment Net Sales
 		Three Months Ended
September 30, 		Nine Months Ended
September 30,
(in thousands) 2026 2025 2026 2025
Human Nutrition & Health $ 188,227 $ 174,088 $ 536,749 $ 493,318
Animal Nutrition & Health 62,990 56,376 189,633 169,681
Specialty Products 37,294 35,683 112,532 106,143
Other and Unallocated (1)
2,147 1,411 6,450 4,402
Total $ 290,658 $ 267,558 $ 845,364 $ 773,544
Business Segment Earnings From Operations
 		Three Months Ended
September 30, 		Nine Months Ended
September 30,
(in thousands) 2026 2025 2026 2025
Human Nutrition & Health $ 45,633 $ 40,831 $ 128,034 $ 117,147
Animal Nutrition & Health 6,789 3,713 17,708 12,463
Specialty Products 12,301 11,534 37,129 32,388
Other and Unallocated (1)
(2,286) (1,499) (5,587) (4,962)
Total $ 62,437 $ 54,579 $ 177,284 $ 157,036
(1) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of transaction and integration costs of $578 and $1,495 for the three and nine months ended September 30, 2026, respectively, and $333 and $1,227 for the three and nine months ended September 30, 2025, respectively.
Results of Operations - Three Months Ended September 30, 2026 and 2025
Net Earnings
Three Months Ended September 30, Increase
(Decrease)
(in thousands) 2026 2025 % Change
Net sales $ 290,658 $ 267,558 $ 23,100 8.6 %
Gross margin 105,714 95,453 10,261 10.7 %
Operating expenses 43,277 40,874 2,403 5.9 %
Earnings from operations 62,437 54,579 7,858 14.4 %
Interest and other expenses 2,393 2,535 (142) (5.6) %
Income tax expense 13,316 11,755 1,561 13.3 %
Net earnings $ 46,728 $ 40,289 $ 6,439 16.0 %
Net Sales
Three Months Ended September 30, Increase
(Decrease)
(in thousands) 2026 2025 % Change
Human Nutrition & Health $ 188,227 $ 174,088 $ 14,139 8.1 %
Animal Nutrition & Health 62,990 56,376 6,614 11.7 %
Specialty Products 37,294 35,683 1,611 4.5 %
Other 2,147 1,411 736 52.2 %
Total $ 290,658 $ 267,558 $ 23,100 8.6 %
•The increase in net sales within the Human Nutrition & Health segment for the third quarter of 2026 as compared to the third quarter of 2025 was driven by higher sales within both the nutrients business and the food ingredients and solutions businesses. Total sales for this segment grew 8.1%, with volume and mix contributing 12.7%, the change in foreign currency exchange rates contributing -0.2%, and average selling prices contributing -4.4%.
•The increase in net sales within the Animal Nutrition & Health segment for the third quarter of 2026 compared to the third quarter of 2025 was driven by higher sales in both the monogastric and ruminant species markets. Total sales for this segment increased by 11.7%, with average selling prices contributing 8.5%, volume and mix contributing 3.6%, and the change in foreign currency exchange rates contributing -0.4%.
•The increase in net sales within the Specialty Products segment for the third quarter of 2026 compared to the third quarter of 2025 was due to higher sales in the performance gases business. Total sales for this segment increased by 4.5%, with average selling prices contributing 7.6%, the change in foreign currency exchange rates contributing -0.2%, and volume and mix contributing -2.8%.
•Sales may fluctuate in future periods based on macroeconomic conditions, competitive dynamics, changes in customer preferences, and our ability to successfully introduce new products to the market.
Gross Margin
Three Months Ended September 30, Increase
(Decrease)
(in thousands) 2026 2025 % Change
Gross margin $ 105,714 $ 95,453 $ 10,261 10.7 %
% of net sales 36.4 % 35.7 %
Gross margin dollars increased in the third quarter of 2026 compared to the third quarter of 2025 due to sales growth, favorable mix and manufacturing efficiencies, partially offset by certain higher manufacturing input costs.
Operating Expenses
Three Months Ended September 30, Increase
(Decrease)
(in thousands) 2026 2025 % Change
Operating expenses $ 43,277 $ 40,874 $ 2,403 5.9 %
% of net sales 14.9 % 15.3 %
The increase in operating expenses in the third quarter of 2026 compared to the third quarter of 2025 was primarily due to higher compensation-related costs of $3,743 and a non-cash impairment charge of $1,915 on certain manufacturing equipment that will not be placed into service, partially offset by a $4,000 favorable legal settlement.
Earnings from Operations
Three Months Ended September 30, Increase
(Decrease)
(in thousands) 2026 2025 % Change
Human Nutrition & Health $ 45,633 $ 40,831 $ 4,802 11.8 %
Animal Nutrition & Health 6,789 3,713 3,076 82.8 %
Specialty Products 12,301 11,534 767 6.6 %
Other and unallocated (2,286) (1,499) (787) (52.5) %
Earnings from operations $ 62,437 $ 54,579 $ 7,858 14.4 %
% of net sales (operating margin) 21.5 % 20.4 %
•Human Nutrition & Health segment earnings from operations increased $4,802, primarily due to a gross margin contribution of $6,312 driven by higher sales and favorable mix.
•Animal Nutrition & Health segment earnings from operations increased $3,076, primarily due to a gross margin contribution of $3,224, which was driven by higher sales and favorable mix, partially offset by certain higher manufacturing input costs.
•Specialty Products segment earnings from operations increased $767 primarily due to a gross margin contribution of $1,161, driven by higher sales and favorable mix.
Other Expenses
Three Months Ended September 30, Increase
(Decrease)
(in thousands) 2026 2025 % Change
Interest expense, net $ 1,934 $ 2,629 $ (695) (26.4) %
Other expense (income), net 459 (94) 553 588.3 %
$ 2,393 $ 2,535 $ (142) (5.6) %
Interest expense for the three months ended September 30, 2026 and 2025 was primarily related to outstanding borrowings under the 2022 Credit Agreement and the Credit Agreement Amendment. The decrease in net interest expense is a reflection of lower outstanding borrowings and lower interest rates. The increase in net other expense for the three months ended September 30, 2026 and 2025 was primarily related to unrealized losses on rabbi trust funds.
Income Tax Expense
Three Months Ended September 30, Increase
(Decrease)
(in thousands) 2026 2025 % Change
Income tax expense $ 13,316 $ 11,755 $ 1,561 13.3 %
Effective tax rate 22.2 % 22.6 %
The lower effective tax rate was primarily due to higher favorable adjustments related to the filing of the prior year federal tax return and a higher foreign-derived intangible income deduction benefit, partially offset by an increase in certain state taxes.
Results of Operations - Nine Months Ended September 30, 2026 and 2025
Net Earnings
Nine Months Ended September 30, Increase
(Decrease)
(in thousands) 2026 2025 % Change
Net sales $ 845,364 $ 773,544 $ 71,820 9.3 %
Gross margin 310,481 276,734 33,747 12.2 %
Operating expenses 133,197 119,698 13,499 11.3 %
Earnings from operations 177,284 157,036 20,248 12.9 %
Interest and other expenses 6,937 8,041 (1,104) (13.7) %
Income tax expense 38,719 33,375 5,344 16.0 %
Net earnings $ 131,628 $ 115,620 $ 16,008 13.8 %
Net Sales
Nine Months Ended September 30, Increase
(Decrease)
(in thousands) 2026 2025 % Change
Human Nutrition & Health $ 536,749 $ 493,318 $ 43,431 8.8 %
Animal Nutrition & Health 189,633 169,681 19,952 11.8 %
Specialty Products 112,532 106,143 6,389 6.0 %
Other 6,450 4,402 2,048 46.5 %
Total $ 845,364 $ 773,544 $ 71,820 9.3 %
•The increase in net sales within the Human Nutrition & Health segment for the nine months ended September 30, 2026 as compared to 2025 was driven by higher sales within both the nutrients business and the food ingredients and solutions businesses. Total sales for this segment grew 8.8%, with volume and mix contributing 9.1%, the change in foreign currency exchange rates contributing 0.6%, and average selling prices contributing -0.8%.
•The increase in net sales within the Animal Nutrition & Health segment for the nine months ended September 30, 2026 as compared to 2025 was driven by higher sales in both the monogastric and ruminant species markets. Total sales for this segment increased by 11.8%, with average selling prices contributing 7.2%, volume and mix contributing 3.8%, and the change in foreign currency exchange rates contributing 0.8%.
•The increase in net sales within the Specialty Products segment for the nine months ended September 30, 2026 as compared to 2025 was due to higher sales in the performance gases business. Total sales for this segment increased by 6.0%, with average selling prices contributing 5.3%, the change in foreign currency exchange rates contributing 1.3%, and volume and mix contributing -0.6%.
•Sales may fluctuate in future periods based on macroeconomic conditions, competitive dynamics, changes in customer preferences, and our ability to successfully introduce new products to the market.
Gross Margin
Nine Months Ended September 30, Increase
(Decrease)
(in thousands) 2026 2025 % Change
Gross margin $ 310,481 $ 276,734 $ 33,747 12.2 %
% of net sales 36.7 % 35.8 %
Gross margin dollars increased in the nine months ended September 30, 2026 as compared to 2025 due to the sales growth, favorable mix, and manufacturing efficiencies, partially offset by certain higher manufacturing input costs.
Operating Expenses
Nine Months Ended September 30, Increase
(Decrease)
(in thousands) 2026 2025 % Change
Operating expenses $ 133,197 $ 119,698 $ 13,499 11.3 %
% of net sales 15.8 % 15.5 %
The increase in operating expenses in the nine months ended September 30, 2026 as compared to 2025 was primarily due to an increase in compensation-related costs of $11,816.
Earnings from Operations
Nine Months Ended September 30, Increase
(Decrease)
(in thousands) 2026 2025 % Change
Human Nutrition & Health $ 128,034 $ 117,147 $ 10,887 9.3 %
Animal Nutrition & Health 17,708 12,463 5,245 42.1 %
Specialty Products 37,129 32,388 4,741 14.6 %
Other and unallocated (5,587) (4,962) (625) (12.6) %
Earnings from operations $ 177,284 $ 157,036 $ 20,248 12.9 %
% of net sales (operating margin) 21.0 % 20.3 %
•Human Nutrition & Health segment earnings from operations increased $10,887, primarily due to a gross margin contribution of $18,812 driven by higher sales and favorable mix. This was partially offset by a $7,922 increase in operating expenses, primarily due to higher compensation-related costs of $5,359.
•Animal Nutrition & Health segment earnings from operations increased $5,245, primarily due to a gross margin contribution of $8,674 driven by higher sales partially offset by a $3,429 increase in operating expenses, primarily due to higher compensation-related costs of $3,764.
•Specialty Products segment earnings from operations increased $4,741, primarily due to a gross margin contribution of $6,295 driven by higher sales and favorable mix, partially offset by a $1,553 increase in operating expenses, primarily due to higher compensation-related costs of $2,426.
Other Expenses
Nine Months Ended September 30, Increase
(Decrease)
(in thousands) 2026 2025 % Change
Interest expense, net $ 6,085 $ 8,319 $ (2,234) (26.9) %
Other expense (income), net 852 (278) 1,130 406.5 %
$ 6,937 $ 8,041 $ (1,104) (13.7) %
Interest expense for the nine months ended September 30, 2026 and 2025 was primarily related to outstanding borrowings under the 2022 Credit Agreement and the Credit Agreement Amendment. The decrease in net interest expense is reflects lower outstanding borrowings and lower interest rates. The increase in net other expense for the nine months ended September 30, 2026 and 2025 was primarily related to foreign currency losses.
Income Tax Expense
Nine Months Ended September 30, Increase
(Decrease)
(in thousands) 2026 2025 % Change
Income tax expense $ 38,719 $ 33,375 $ 5,344 16.0 %
Effective tax rate 22.7 % 22.4 %
The higher effective tax rate was primarily due to an increase in certain state taxes, partially offset by higher favorable adjustments related to the filing of the prior year federal tax return.
Liquidity and Capital Resources
During the nine months ended September 30, 2026, there were no material changes outside the ordinary course of business in the specified contractual obligations set forth in our Annual Report on Form 10-K for the year ended December 31, 2025. We expect our operations to continue generating sufficient cash flow to fund working capital requirements and necessary capital investments. We are actively pursuing additional acquisition candidates. We could seek additional bank loans or access to financial markets to fund such acquisitions, our operations, working capital, necessary capital investments or other cash requirements should we deem it necessary to do so.
Cash
Cash and cash equivalents decreased to $66,264 at September 30, 2026 from $74,570 at December 31, 2025. At September 30, 2026, the Company had $57,919 of cash and cash equivalents held by foreign subsidiaries. We intend to permanently reinvest a significant portion of these foreign-held funds in foreign operations by continuing to make additional plant related investments, and potentially invest in partnerships or acquisitions; however, we may also repatriate a portion of cash held by certain foreign subsidiaries to support U.S. liquidity needs and capital allocation priorities. To the extent amounts are repatriated, we could be required to pay applicable withholding taxes on such repatriations. During the second quarter of 2026, we repatriated $23,460 from our Belgium subsidiary to pay down U.S. debt. Working capital was $240,762 at September 30, 2026 as compared to $189,230 at December 31, 2025, an increase of $51,532. Significant cash payments during the nine months ended September 30, 2026 included repurchases of common stock of $71,925, net debt payments of $40,000, income taxes paid of $38,586, the payment of dividends declared in 2025 of $30,773, and capital expenditures and intangible assets acquired of $29,605.
Nine Months Ended September 30, Increase
(Decrease)
(in thousands) 2026 2025 % Change
Cash flows provided by operating activities $ 156,544 $ 149,281 $ 7,263 4.9 %
Cash flows used in investing activities (29,753) (27,475) (2,278) (8.3) %
Cash flows used in financing activities (133,205) (111,562) (21,643) (19.4) %
Operating Activities
The increase in cash flows from operating activities was primarily driven by higher net earnings and higher non-cash adjustments, partially offset by changes in working capital, primarily an increase in inventories, partially offset by an increase in accounts payable and accrued expenses.
Investing Activities
We continue to invest in corporate projects, improvements across all production facilities, and intangible assets. Total investments in property, plant and equipment and intangible assets were $29,605 and $27,275 for the nine months ended September 30, 2026 and 2025, respectively.
Financing Activities
During the nine months ended September 30, 2026, we borrowed $88,000 to fund the 2025 dividend, bonus payments, and share repurchases. We made total loan payments of $128,000, resulting in $526,000 available under the revolving credit facility (see Note 7, Revolving Loan) as of September 30, 2026.
On July 24, 2026, the Company entered into the Credit Agreement Amendment, which expands our ability to fund growth, innovation, and acquisitions. The Credit Agreement Amendment increased the aggregate revolving commitment amount from $550,000 to $650,000, extended the maturity date of the credit facility from July 27, 2027 to July 24, 2031, and made certain other amendments to the facility terms. The Company used initial proceeds from the Credit Agreement Amendment to repay the outstanding balance of $152,000 due in July 2027 under the 2022 Credit Agreement.
On December 9, 2025, the Company's Board of Directors approved a stock repurchase program (the "December 2025 program"), which replaced the previously approved June 1999 program. The December 2025 program authorizes the repurchases of up to and including 4,000,000 shares of the Company's ordinary shares. The stock repurchase program has no expiration date, does not oblige the Company to acquire any particular amount of the Company's ordinary shares, and may be terminated at any time. Since the inception of the December 2025 program, a total of 513,406 shares have been repurchased. We intend to acquire shares from time to time at prevailing market prices if and to the extent we deem it is advisable to do so based on our assessment of corporate cash flow, market conditions and other factors. Open market repurchases of common stock could be made pursuant to a share repurchase agreement in compliance with Rule 10b-18 or a trading plan established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, which would permit common stock to be repurchased at a time that we might otherwise be precluded from doing so under insider trading laws or self-imposed trading restrictions. We also repurchase (withhold) shares from employees in connection with the tax settlement of vested shares and/or exercised stock options, as applicable, under the Company's omnibus incentive plan. Such repurchases of shares from employees are funded with existing cash on hand. Repurchases of common stock were $71,925 and $54,008 for the nine months ended September 30, 2026 and 2025, respectively.
Proceeds from stock options exercised were $11,589 and $6,867 for the nine months ended September 30, 2026 and 2025, respectively. Dividend payments were $30,773 and $28,276 for the nine months ended September 30, 2026 and 2025, respectively.
Other Matters Impacting Liquidity
As of September 30, 2026 and December 31, 2025, we have a liability of $7,052 and $6,731, respectively, for uncertain tax positions, including the related interest and penalties, recorded in accordance with ASC 740-10, for which we are unable to reasonably estimate the timing of settlement, if any.
We currently provide postretirement benefits in the form of two retirement medical plans, as discussed in Note 14, Employee Benefit Plans. The liabilities recorded in "Other long-term obligations" on the condensed consolidated balance sheets as of September 30, 2026 and December 31, 2025 were $1,147 and $1,122, respectively, and the plans are not funded. Historical cash payments made under these plans have typically been less than $200 per year. We do not anticipate any changes to the payments made in the current year for the plans.
We provide an unfunded defined benefit pension plan for employees working in Belgium. The plan provides for the payment of a lump sum at retirement or payments in case of death of the covered employees. The amounts recorded for this obligation on our balance sheets as of September 30, 2026 and December 31, 2025 was $938 and $869, respectively, and was included in "Other long-term obligations" on the condensed consolidated balance sheets.
We provide an unfunded, nonqualified deferred compensation plan maintained for the benefit of a select group of management or highly compensated employees. Assets of the plan are held in a rabbi trust and are subject to additional risk of loss in the event of bankruptcy or insolvency of the Company. The deferred compensation liability was $14,273 as of September 30, 2026, of which $13,246 was included in "Other long-term obligations" and $1,027 was included in "Accrued compensation and other benefits" on our consolidated balance sheets. The deferred compensation liability was $12,806 as of December 31, 2025, of which $12,781 was included in "Other long-term obligations" and $25 was included in "Accrued compensation and other benefits" on our consolidated balance sheets. The related rabbi trust assets were $14,262 as of September 30, 2026, of which $13,234 was included in "Other non-current assets" and $1,028 was included in "Other current assets" on the condensed consolidated balance sheets. The rabbi trust assets were $12,798 as of December 31, 2025, of which $12,773 was included in "Other non-current assets" and $25 was included in "Other current assets" on the Company's condensed consolidated balance sheets.
Significant Accounting Policies
There were no changes to our Significant Accounting Policies, as described in our December 31, 2025 Annual Report on Form 10-K, during the nine months ended September 30, 2026.
Related Party Transactions
We were engaged in related party transactions with St. Gabriel CC Company, LLC during the three and nine months ended September 30, 2026. Refer to Note 17, Related Party Transactions.
Balchem Corporation published this content on October 23, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on October 23, 2026 at 20:19 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]